Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market

Big pharma stocks

Key Points

  • Novartis achieved strong earnings fueled by the success of key drugs like Entresto, Kisqali, and Kesimpta.
  • Novartis plans to spin off its generics business, Sandoz, to further boost growth.
  • Eli Lilly's stock is trading at record highs, driven by optimism about Alzheimer's treatment, donanemab.
  • Merck exceeded Wall Street views with the sales of cancer treatment Keytruda and Gardasil.
  • Novo Nordisk has seen growing sales of weight loss drug Wegovy, while Saxenda and Ozempic showed growth potential.
  • 5 stocks we like better than Novartis

Big pharmaceutical stocks, including Novartis AG NYSE: NVS, Eli Lilly & Co. NYSE: LLY, Merck & Co. NYSE: MRK, and Novo Nordisk A/S NYSE: NVO have been outperforming the broader market recently, even as the healthcare sector as a whole lags. 

Pharmaceutical stocks aren’t immune to either a poor economy or a downward-trending market, but they do tend to book more consistent sales and earnings than companies whose products are considered more discretionary.

On the other hand, these stocks are prone to move based on government actions. For example, if the federal government successfully negotiates lower costs for medicines it purchases for Medicare and Medicaid plans, pharmaceutical profits will be slashed and research and development may be severely curtailed.

On the flip side, Medicare and Medicaid reimbursement changes can sometimes benefit pharmaceuticals and medical device makers, as occurred recently with Shockwave Medical Inc. NASDAQ: SWAV

Here’s a look at how a few big pharma stocks are outpacing the wider market.

Novartis

Novartis stock is trading below its April 25 all-time high of 105.56, but in a sign of strength, is still holding 7.1% above its 50-day average. 

Novartis earnings show that the company easily beat top and bottom-line views in the most recent quarter, driven by the success of three key drugs: Entresto, Kisqali, and Kesimpta. 


Entresto, an effective heart failure treatment, contributed to a 32% surge in sales. Kisqali, used in breast cancer treatment, and Kesimpta, a multiple sclerosis medicine, notched revenue growth of 81% and 100% respectively. Overall, earnings were up 17% while revenue grew by 3%.

Despite the positive results and new price highs, Novartis analyst ratings show a consensus of “hold” on the stock, with a price target of $85, a downside of 16.25%. While analysts are optimistic about the company’s long-term prospects, they believe mid-term growth may be challenging. 

Novartis also confirmed its plan to spin off its generics business, Sandoz, in the second half of this year. The new Sandoz shares may provide an extra growth boost for those currently owning Novartis stock.

Eli Lilly

The Eli Lilly chart shows the stock trading at record highs, partly on optimism that the company's experimental Alzheimer's treatment, donanemab can achieve blockbuster status by 2025. On May 3, the company announced positive results from a Phase III clinical trial, sending Eli Lilly stock up 6.68% in three times average volume.

Analysts project that donanemab could generate $465 million in sales in 2024, followed by $1.4 billion in 2025 and $3.2 billion in 2030. The drug, administered through intravenous infusion, slows cognitive decline in Alzheimer's patients. Eli Lilly is also working on a subcutaneous injection and an oral treatment for Alzheimer's.

Eli Lilly's success extends beyond Alzheimer's treatment. Its diabetes drug, Mounjaro, also leads to significant weight loss in patients. Eli Lilly plans to submit data to the FDA for approval as an obesity treatment.

Year-over sales and earnings declined in the past two quarters, largely due to sharp decreases in sales of Covid antibodies. Many pharmaceuticals are no longer breaking out sales of Covid-related treatments as their importance diminishes rapidly. 

Eli Lilly analyst ratings show a “moderate buy” view on the stock. Since April 28, 10 analysts boosted their targets on the stock. 

Merck

The Merck chart shows that the stock pulled back from its May 3 record high, but is holding 2.1% above its 50-day average, as well as above its April 27 structure low of $110.66.

Merck earnings data show the company exceeded Wall Street's expectations in the first quarter, with growth primarily driven by the sales of cancer treatment Keytruda, which surged 20% to nearly $5.8 billion, ahead of analysts’ views. Merck's human papillomavirus vaccine, Gardasil, also contributed to the positive results with sales of $1.97 billion, a 35% increase.

However, sales of Merck's Covid pill, Lagevrio, fell at a double-digit rate. That’s consistent with other companies’ declining Covid-related sales. 

Despite challenges, including declining sales of diabetes drug Januvia, Merck raised its sales outlook for the year to a range between $57.7 billion and $58.9 billion, and said it expects net income between $6.88 and $7 per share. 

Wall Street expects earnings of $6.97 this year, down 7%. Next year, analysts see growth resuming, with net income of $8.50 per share, up 22%.

Merck stock may be forming a consolidation below its May 3 high of $119.65; if the stock finds a floor above its 50-day line, that could offer a new buy zone. 

Novo Nordisk

Novo Nordisk shares have been trading in a narrow range recently, down 0.56% in the past month as the stock pulls back from an April 21 record high of $172.97. 

Novo Nordisk’s recent results show that investors can be very demanding: In the most recent quarter, the company’s weight loss drug, Wegovy, fell short of revenue expectations, although sales grew 240% to $676.8 million.

Obesity treatment Saxenda brought in $486.4 million, exceeding expectations. The company’s diabetes drug Ozempic has also shown potential for weight loss. Ozempic sales grew 74% to $2.91 billion in the quarter, ahead of expectations. 

Novo Nordisk earnings came in at $1.28, up 38% from the year-earlier quarter. Revenue of $7.767 billion represented an increase of 24%. 

Novo Nordisk analyst ratings show a “moderate buy” consensus on the stock. 

Morningstar analyst Karen Andersen is maintaining her fair value estimate on the stock, writing, “We think Novo Nordisk’s wide moat, based on innovation in diabetes and other cardiometabolic diseases, remains solid, although we think shares look overvalued at recent prices, given our uncertainty around the long-term sustainability of Novo’s increasingly semaglutide-reliant growth.”

Semaglutide is the pharmaceutical name for both Wegovy and Ozempic.  

Andersen added that Novo Nordisk’s track record for innovation bodes well for the development of new combination regimens in diabetes and obesity. 

Should you invest $1,000 in Novartis right now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Novartis (NVS)
2.4535 of 5 stars
$102.55-0.1%2.37%13.84Hold$115.00
Eli Lilly and Company (LLY)
4.8435 of 5 stars
$770.00-0.1%0.68%113.40Moderate Buy$769.53
Merck & Co., Inc. (MRK)
4.7474 of 5 stars
$131.19+0.2%2.35%145.77Moderate Buy$131.33
Novo Nordisk A/S (NVO)
1.6756 of 5 stars
$131.89-0.9%1.01%45.48Moderate Buy$133.60
Shockwave Medical (SWAV)
4.4351 of 5 stars
$330.13-0.2%N/A77.13Hold$309.11
Compare These Stocks  Add These Stocks to My Watchlist 

Kate Stalter

About Kate Stalter

  • stalterkate@gmail.com

Contributing Author

Retirement, Asset Allocation, and Tax Strategies

Experience

Kate Stalter has been a contributing writer for MarketBeat since 2021.

Additional Experience

Series 65-licensed investment advisor, financial advisor, Blue Marlin Advisors; investment columnist for Forbes, U.S. News & World Report

Areas of Expertise

Asset allocation, technical and fundamental analysis, retirement strategies, income generation, risk management, sector and industry analysis

Education

Bachelor of Arts, Saint Mary’s College, Notre Dame, Indiana; Master of Business Adminstration, Kellogg School of Management at Northwestern University

Past Experience

Founder, financial advisor for Better Money Decisions; editor, stock trading instructor for Investor’s Business Daily; columnist, podcast host, video host for MoneyShow.com; contributor for Morningstar magazine


Featured Articles and Offers

Search Headlines: